Instytut Genetyki i Immunologii GENIM
About Instytut Genetyki i Immunologii GENIM
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Amgen
2
Hoffmann-La Roche
1
Jiangsu HengRui Medicine Co., Ltd.
1
Clinical Trials at Instytut Genetyki i Immunologii GENIM
During the past decade, Instytut Genetyki i Immunologii GENIM conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
2020-06-04
2026-04-27
Active, not recruiting
345
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
2020-09-11
2023-10-31
Active, not recruiting
151
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
2020-08-27
2026-12-31
Recruiting
15,000
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
2022-03-29
2025-10-31
Recruiting
180
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Instytut Genetyki i Immunologii GENIM
According to Clinical.Site data, the most researched conditions in "Instytut Genetyki i Immunologii GENIM" are
"HER2 Exon 20 Mutation" (1 trials), "KRAS p, G12c Mutated /Advanced Metastatic NSCLC" (1 trials), "Non-squamous NSCLC" (1 trials), "Solid Tumours" (1 trials) and "Squamous-Cell Non-Small-Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Instytut Genetyki i Immunologii GENIM" in a lesser frequency.
Clinical Trials Intervention Types at Instytut Genetyki i Immunologii GENIM
Most popular intervention types in "Instytut Genetyki i Immunologii GENIM" are "Drug" (3 trials). Other intervention types were less common.
The name of intervention was led by "Docetaxel" (3 trials), "AMG 510" (1 trials), "Bemarituzumab" (1 trials), "Carboplatin" (1 trials) and "Nab-paclitaxel" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Instytut Genetyki i Immunologii GENIM
The vast majority of trials in "Instytut Genetyki i Immunologii GENIM" are
4 trials for "All" genders.
Clinical Trials Status at Instytut Genetyki i Immunologii GENIM
Currently, there are NaN active trials in "Instytut Genetyki i Immunologii GENIM".
undefined are not yet recruiting,
2 are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Instytut Genetyki i Immunologii GENIM,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Instytut Genetyki i Immunologii GENIM, 1 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".